A Relative Bioavailability Study of Gabapentin Tablets 800 mg Under Non-fasting Conditions

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2001
The purpose of this study is to compare the relative bioavailability of 800 mg Gabapentin Tablets by Purepac Pharmaceutical Co. with that of 800 mg NEURONTIN® Tablets by Parke-Davis following a single oral dose (1 x 800 mg) in healthy adult volunteers under non-fasting conditions.
Epistemonikos ID: 304ce3611a8d757f93e8c181df209f78be40024a
First added on: May 05, 2024